Cardio-oncology & otherMeta-analysis
American Heart Association cardiovascular health metrics and cancer outcomes: A systematic review and meta-analysis
- systematic review and meta-analysis
- meta regression
Authors' conclusion
We provide evidence for a dose response association of better CVH scores with decreased cancer incidence and cancer mortality. Optimizing CVH may improve cancer outcomes.
Study context
- Population
- Cohort studies examining the association of American Heart Association (AHA) cardiovascular health (CVH) metrics with cancer risk and cancer mortalitystudies included in the systematic review
- Participants
- 26 studies
- Comparison
- low, moderate, and high CVH score groups
Pooled result
As reported in the abstract
Overall cancer risk
Each group vs low (worse)Relative risk (95% CI)P value
moderate
0.85(0.79–0.91)
P < 0.001high (best)
0.72(0.64–0.81)
P < 0.001- dose-response coefficient
- −0.09; standard error [SE], 0.02; P < .001
Further pooled results
| Outcome | Estimate | P value | |
|---|---|---|---|
| Breast, colorectal and lung cancer risk — high (best) vs low (worse) · breast | RR 0.72 (95% CI 0.58–0.90) | ||
| Breast, colorectal and lung cancer risk — high (best) vs low (worse) · colorectal | RR 0.65 (95% CI 0.57–0.74) | ||
| Breast, colorectal and lung cancer risk — high (best) vs low (worse) · lung | RR 0.34 (95% CI 0.16–0.70) | ||
| Cancer mortality — moderate vs low (worse) | HR 0.64 (95% CI 0.61–0.68) | P < 0.001 | |
| Cancer mortality — high (best) vs low (worse) | HR 0.47 (95% CI 0.41–0.53) | P < 0.001 | |
| 0.10.31310Ratio (log scale) |
- Cancer mortality — Meta regression dose-response coefficient, all cancer mortality
- −0.33; SE, 0.05; P < .001
Original publication
American Heart Association cardiovascular health metrics and cancer outcomes: A systematic review and meta-analysis. Am Heart J. Published 18 March 2026. doi:10.1016/j.ahj.2026.107426
Summarised from the published abstract; every number is checked against it